Clinical Trial Update: A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TACE sequential tislelizumab as adjuvant therapy for hepatocellular carcinoma at high risk of recurrence after curative resection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Zhejiang University | Conditions: Hepatocellular Carcinoma, Adjuvant Therapy | Phase 2 | Status: UNKNOWN